Palbociclib and Letrozole in Advanced Breast Cancer | Zendy

Richard S. Finn | Zendy; Miguel Martín | Zendy; Hope S. Rugo | Zendy; Stephen E. Jones | Zendy; SeockAh Im | Zendy; Karen A. Gelmon | Zendy; Nadia Harbeck | Zendy; O. N. Lipatov | Zendy; Janice M. Walshe | Zendy; Stacy Moulder | Zendy; Eric Gauthier | Zendy; Dongrui R. Lu | Zendy; Sophia Randolph | Zendy; Véronique Dièras | Zendy; Dennis J. Slamon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Palbociclib and Letrozole in Advanced Breast Cancer

Author(s) -

Richard S. Finn,

Miguel Martín,

Hope S. Rugo,

Stephen E. Jones,

SeockAh Im,

Karen A. Gelmon,

Nadia Harbeck,

O. N. Lipatov,

Janice M. Walshe,

Stacy Moulder,

Eric Gauthier,

Dongrui R. Lu,

Sophia Randolph,

Véronique Dièras,

Dennis J. Slamon

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1607303

Subject(s) - palbociclib , letrozole , medicine , breast cancer , oncology , estrogen receptor , cancer , gynecology , metastatic breast cancer , tamoxifen

A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research